Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells (…)
The relatively small payment reflects that “it’s really early for cell therapy and there’s more research to be done,” said Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, a unit created by the company about 18 months ago to develop treatments based on stem cells (…)
Image by Marcos (In the fast lane) via Flickr
Culturing stem cells to use to treat certain illnesses is already a reality. In Spain, two labs have received authorization from the Agencia Espanola de Medicamento y Productos Sanitarios to produce stem cells, and there are others waiting to be certified.
Currently, just one public health center, the Gregorio Maranon Hospital in Madrid (HGM) and one private center, the Clinica Universitaria in Navarra (CUN) have undergone the rigid system of quality certification to become “Good Manufacturing Regulations” (GMR) laboratories and are developing stem cell products to be administered and transplanted into
Image by Getty Images via Daylife
After Barack Obama’s victory in the U.S. presidential elections, the economic community, in the middle of a recession and the worst financial crisis in the past decades, continues to hold its breath. The Democrat’s victory induce change and potentially more difficult times for the energy, pharmaceutical, telecommunications, and defense sectors, while the biotechnology and alternative energy sectors could be strengthened by the outcome of the elections. Obama has promised to increase investments in wind and solar energy and to spend 150 billion dollars in 10 years to hasten the development of